ReviewInternational journal of molecular sciences2021
Perioperative Systemic Treatment for Muscle-Invasive Bladder Cancer: Current Evidence and Future Perspectives.
Review in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 27 citations in OpenAlex.
- Integrative analysis identifies candidate biomarkers for bladder cancer: evidence from genomic and clinical validation.Molecular biology reports · 2026Article
- Neoadjuvant disitamab vedotin (RC-48) plus a PD-1 inhibitor in muscle-invasive bladder cancer: a multicenter real-world study with stratification by HER2 expression and tertiary lymphoid structures.Frontiers in immunology · 2026Observational
- Article
- Application of Immune Checkpoint Inhibitors in Cancer.MedComm · 2025Review
- Immunotherapeutic strategies for invasive bladder cancer: a comprehensive review.Frontiers in immunology · 2025Review
- PD-L1 expression and its correlation with tumor biomarkers in Chinese urothelial bladder cancer.Scientific reports · 2024Observational
- A narrative review of management of muscle-invasive bladder cancer perioperative period: will continuous and combined treatment be the new trend?Translational andrology and urology · 2024Review
- CUDC‑101 is a potential target inhibitor for the EGFR‑overexpression bladder cancer cells.International journal of oncology · 2023Article
- Current and Future Landscape of Perioperative Treatment for Muscle-Invasive Bladder Cancer.Cancers · 2023Review
- Prognostic nomogram for estimating survival in patients with resected muscle-invasive bladder cancer receiving chemotherapy.Frontiers in surgery · 2023Article
- Characterization of the Lipid Metabolism in Bladder Cancer to Guide Clinical Therapy.Journal of oncology · 2022Article
- Tumor-Associated Mast Cells in Urothelial Bladder Cancer: Optimizing Immuno-Oncology.Biomedicines · 2021Review
- Genistein Exerts Anti-proliferative Effects by Regulating Apoptosis and Autophagy-Related Genes and MicroRNAs in Human Urinary Bladder Neoplasm EJ138 Cells: An Experimental and Bioinformatic Study.Iranian journal of pharmaceutical research : IJPRArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Radical cystectomy is the primary treatment for muscle-invasive bladder cancer; however, approximately 50% of patients develop metastatic disease within 2 years of diagnosis, which results in dismal prognosis. Therefore, systemic treatment is important to improve the prognosis of muscle-invasive bladder cancer. Currently, several guidelines recommend cisplatin-based neoadjuvant chemotherapy before radical cystectomy, and adjuvant chemotherapy is recommended in patients who have not received neoadjuvant chemotherapy. Immune checkpoint inhibitors have recently become the standard treatment option for metastatic urothelial carcinoma. Owing to their clinical benefits, several immune checkpoint inhibitors, with or without other agents (including other immunotherapy, cytotoxic chemotherapy, and emerging agents such as antibody drug conjugates), are being extensively investigated in perioperative settings. Several studies for perioperative immunotherapy have shown that immune checkpoint inhibitors have promising efficacy with relatively low toxicity, and have explored the predictive molecular biomarkers. Herein, we review the current evidence and discuss the future perspectives of perioperative systemic treatment for muscle-invasive bladder cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.